Literature DB >> 23066870

Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis.

Yingyun Liu1, Arne Schön, Ernesto Freire.   

Abstract

As protein/protein interactions usually trigger signalling processes, inhibitors of those interactions must preclude protein binding without eliciting the signalling process themselves. To accomplish those goals, small molecules need to target those protein residues that contribute the most to binding (binding hotspots) without disturbing those residues that initiate signalling processes (allosteric hotspots). The availability of a blueprint identifying binding and allosteric hotspots will significantly aid inhibitor design and optimization. In this study, we show that in some situations the blueprint can be constructed by combining the standard technique of alanine-scanning mutagenesis with isothermal titration calorimetry (ITC). We demonstrate the approach by developing the combined binding and allosteric hotspots blueprint for CD4/gp120, the initial interaction leading to HIV-1 cell infection. A major finding of these studies is that not all binding hotspots are allosteric hotspots opening the possibility for the rational design of inhibitors and antagonist or agonist modulators.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23066870      PMCID: PMC3527665          DOI: 10.1111/cbdd.12075

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  34 in total

1.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Some binding-related drug properties are dependent on thermodynamic signature.

Authors:  Arne Schön; Navid Madani; Amos B Smith; Judith M Lalonde; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2011-02-02       Impact factor: 2.817

3.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

Review 4.  Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.

Authors:  James A Wells; Christopher L McClendon
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

Review 5.  Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions.

Authors:  Arne Schön; Sonia Y Lam; Ernesto Freire
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

6.  Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.

Authors:  Judith M LaLonde; Young Do Kwon; David M Jones; Alexander W Sun; Joel R Courter; Takahiro Soeta; Toyoharu Kobayashi; Amy M Princiotto; Xueling Wu; Arne Schön; Ernesto Freire; Peter D Kwong; John R Mascola; Joseph Sodroski; Navid Madani; Amos B Smith
Journal:  J Med Chem       Date:  2012-04-23       Impact factor: 7.446

7.  The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.

Authors:  Hiroko Shibata; Yasuo Yoshioka; Akiko Ohkawa; Yasuhiro Abe; Tetsuya Nomura; Yohei Mukai; Shinsaku Nakagawa; Madoka Taniai; Tsunetaka Ohta; Tadanori Mayumi; Haruhiko Kamada; Shin-ichi Tsunoda; Yasuo Tsutsumi
Journal:  Cytokine       Date:  2008-09-23       Impact factor: 3.861

8.  Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization.

Authors:  Scott T R Walsh; Liz M Jevitts; Juliesta E Sylvester; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

Review 9.  Small-molecule inhibitors of protein-protein interactions.

Authors:  Thorsten Berg
Journal:  Curr Opin Drug Discov Devel       Date:  2008-09

10.  Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

Authors:  Evan T Brower; Arne Schön; Ernesto Freire
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

View more
  13 in total

1.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

2.  Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120.

Authors:  Alexander M Andrianov; Ivan A Kashyn; Alexander V Tuzikov
Journal:  J Mol Model       Date:  2017-01-03       Impact factor: 1.810

3.  Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition.

Authors:  Bruno Melillo; Shuaiyi Liang; Jongwoo Park; Arne Schön; Joel R Courter; Judith M LaLonde; Daniel J Wendler; Amy M Princiotto; Michael S Seaman; Ernesto Freire; Joseph Sodroski; Navid Madani; Wayne A Hendrickson; Amos B Smith
Journal:  ACS Med Chem Lett       Date:  2016-01-19       Impact factor: 4.345

4.  Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics.

Authors:  Christopher J Fritschi; Shuaiyi Liang; Mohammadjavad Mohammadi; Saumya Anang; Francesca Moraca; Junhua Chen; Navid Madani; Joseph G Sodroski; Cameron F Abrams; Wayne A Hendrickson; Amos B Smith
Journal:  ACS Med Chem Lett       Date:  2021-10-29       Impact factor: 4.632

5.  Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics.

Authors:  Francesca Moraca; Kriti Acharya; Bruno Melillo; Amos B Smith; Irwin Chaiken; Cameron F Abrams
Journal:  J Chem Inf Model       Date:  2016-09-26       Impact factor: 4.956

6.  Specific Noncovalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small-Molecule CD4 Mimetics and HIV-1 gp120.

Authors:  Francesca Moraca; David Rinaldo; Amos B Smith; Cameron F Abrams
Journal:  ChemMedChem       Date:  2018-02-09       Impact factor: 3.466

7.  Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.

Authors:  Judith M Lalonde; Matthew Le-Khac; David M Jones; Joel R Courter; Jongwoo Park; Arne Schön; Amy M Princiotto; Xueling Wu; John R Mascola; Ernesto Freire; Joseph Sodroski; Navid Madani; Wayne A Hendrickson; Amos B Smith
Journal:  ACS Med Chem Lett       Date:  2013-03-14       Impact factor: 4.345

8.  CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.

Authors:  Navid Madani; Amy M Princiotto; Arne Schön; Judith LaLonde; Yu Feng; Ernesto Freire; Jongwoo Park; Joel R Courter; David M Jones; James Robinson; Hua-Xin Liao; M Anthony Moody; Sallie Permar; Barton Haynes; Amos B Smith; Richard Wyatt; Joseph Sodroski
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

9.  Binding Thermodynamics to Intrinsically Disordered Protein Domains.

Authors:  Arne Schön; Ernesto Freire
Journal:  Methods Mol Biol       Date:  2020

Review 10.  Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.

Authors:  Joel R Courter; Navid Madani; Joseph Sodroski; Arne Schön; Ernesto Freire; Peter D Kwong; Wayne A Hendrickson; Irwin M Chaiken; Judith M LaLonde; Amos B Smith
Journal:  Acc Chem Res       Date:  2014-02-06       Impact factor: 22.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.